Bioxyne Limited (AU:BXN) has released an update.
Bioxyne Limited has expanded its pharmaceutical reach by partnering with Cy Biopharma AG to manufacture and supply Psilocybin products for clinical trials and authorized prescriber schemes across Australia, New Zealand, the US, and Europe. The collaboration includes the development of proprietary formulations and a profit-sharing agreement for the sale of starting materials. Although the financial impact is not yet quantified, the agreement is a strategic move in Bioxyne’s multinational operations in health and wellness products.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.
